These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6040705)

  • 1. Steroids in hematological disease.
    Ingham GK
    Appl Ther; 1967 Feb; 9(2):161-2. PubMed ID: 6040705
    [No Abstract]   [Full Text] [Related]  

  • 2. [Critical remarks on current corticosteroid therapy of systemic blood diseases].
    Demidova AV; Datsenko SF
    Ter Arkh; 1968 Apr; 40(4):64-71. PubMed ID: 5740512
    [No Abstract]   [Full Text] [Related]  

  • 3. [In the treatment of hematopoietic disease with glucocorticosteroids].
    Sakano T; Takenaka T; Narabayashi M
    Nihon Rinsho; 1994 Mar; 52(3):713-8. PubMed ID: 8164372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic uses of methyl prednisolone.
    Mondal T; Kumar KJ; Chandra J
    Indian Pediatr; 1995 Jul; 32(7):787-93. PubMed ID: 8617556
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunosuppressive therapy in hematological diseases. Principles and mechanism of action].
    Frøland SS; Stavem P
    Tidsskr Nor Laegeforen; 1983 Jun; 103(17-18):1391-5. PubMed ID: 6623445
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucocorticoids in clinical oncology.
    Walsh D; Avashia J
    Cleve Clin J Med; 1992; 59(5):505-15. PubMed ID: 1281759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heme in the treatment of porphyrias and hematological disorders.
    Mustajoki P; Tenhunen R; Pierach C; Volin L
    Semin Hematol; 1989 Jan; 26(1):1-9. PubMed ID: 2646718
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
    Hansen PB; Hasselbalch HC
    Ugeskr Laeger; 2004 Feb; 166(6):466-9. PubMed ID: 15045710
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan.
    Ohara S; Fujii T; Ide S; Uchida T; Inoue M; Hagaihara M
    Int J Hematol; 2021 Dec; 114(6):719-724. PubMed ID: 34152562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferons in the treatment of hematological diseases].
    Jantunen E; Nousiainen T
    Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
    [No Abstract]   [Full Text] [Related]  

  • 11. Uses, adverse effects of abuse of corticosteroids. Part I.
    Imam AP; Halpern GM
    Allergol Immunopathol (Madr); 1994; 22(6):250-60. PubMed ID: 7892813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glucocorticoids in hematology and medical oncology].
    Illiger HJ
    Internist (Berl); 1997 May; 38(5):485-8. PubMed ID: 9264992
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of systemic antibiotic therapy on microbial flora of gastrointestinal tract in the hematological patients].
    Bermudez LE; Panza M; Velasco E; Vidal E
    Rev Paul Med; 1984; 102(6):256-9. PubMed ID: 6535218
    [No Abstract]   [Full Text] [Related]  

  • 14. New treatment options for immune-mediated hematological disorders.
    Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
    Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced respiratory disease in patients with hematological diseases.
    Camus P; Costabel U
    Semin Respir Crit Care Med; 2005 Oct; 26(5):458-81. PubMed ID: 16267698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons.
    Silvestri F; Virgolini L; Mazzolini A; Bertolissi F; Russo D; Fanin R; Baccarani M
    Haematologica; 1994; 79(4):367-70. PubMed ID: 7806093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases: a randomized double-blind placebo-controlled study.
    Portugal R; Schaffel R; Almeida L; Spector N; Nucci M
    Haematologica; 2002 Jun; 87(6):663-4. PubMed ID: 12031927
    [No Abstract]   [Full Text] [Related]  

  • 18. Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?
    Cox MC; Marignani M; Veggia B; Angeletti S; Leone F; Cipriani P; Gallina S; Delle Fave G; Aloe-Spiriti MA; Monarca B
    Ann Hematol; 2009 Mar; 88(3):283-4. PubMed ID: 18807036
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drugs used in the treatment of hematologic diseases].
    Takaku F; Maezawa M
    Kango Gijutsu; 1977 Apr; 23(6):85-95. PubMed ID: 585390
    [No Abstract]   [Full Text] [Related]  

  • 20. [(Round table conference). Advances in the treatment of hematologic diseases].
    Nakao K; Miwa S; Maekawa T; Amagi K; Suzuki H
    Naika; 1965 Oct; 16(4):708-24. PubMed ID: 5885635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.